BMS-929075|BMS 929075;BMS929075

Cas No.:	1217338-97-0
Chemical Name:	4-Fluoro-2-(4-fluorophenyl)-N-methyl-5-[2-methyl-5-[[[1-(2-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]-3-benzofurancarboxamide
Synonyms:	BMS 929075;BMS929075
SMILES:	O1C2=CC=C(C3=CC(C(NC(C4=NC=CC=N4)4CC4)=O)=CC=C3C)C(F)=C2C(C(NC)=O)=C1C1=CC=C(F)C=C1
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively; possesses excellent pharmacokinetic parameters across preclinical animal species.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC8612	Simeprevir(TMC-435)	Simeprevir (TMC 435350) is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).
DC8178	Beclabuvir(BMS-791325)	non-nucleoside inhibitor of the NS5B
DC11494	INX-08189	INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay.
DC11081	Coblopasvir	Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection..
DC11731	Ruzasvir	A potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively..
DC11825	MK-8876	A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively.
DC11823	BMS-929075	A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively.